Division of Medical Sciences, National Cancer Centre, Singapore.
Clin Cancer Res. 2013 Aug 15;19(16):4477-87. doi: 10.1158/1078-0432.CCR-12-3401. Epub 2013 Jun 24.
There is a quest for novel noninvasive diagnostic markers for the detection of breast cancer. The goal of this study is to identify circulating microRNA (miRNA) signatures using a cohort of Asian Chinese patients with breast cancer, and to compare miRNA profiles between tumor and serum samples.
miRNA from paired breast cancer tumors, normal tissue, and serum samples derived from 32 patients were comprehensively profiled using microarrays or locked nucleic acid real-time PCR panels. Serum samples from healthy individuals (n = 22) were also used as normal controls. Significant serum miRNAs, identified by logistic regression, were validated in an independent set of serum samples from patients (n = 132) and healthy controls (n = 101).
The 20 most significant miRNAs differentially expressed in breast cancer tumors included miRNA (miR)-21, miR-10b, and miR-145, previously shown to be dysregulated in breast cancer. Only 7 miRNAs were overexpressed in both tumors and serum, suggesting that miRNAs may be released into the serum selectively. Interestingly, 16 of the 20 most significant miRNAs differentially expressed in serum samples were novel. MiR-1, miR-92a, miR-133a, and miR-133b were identified as the most important diagnostic markers, and were successfully validated; receiver operating characteristic curves derived from combinations of these miRNAs exhibited areas under the curves of 0.90 to 0.91.
The clinical use of miRNA signatures as a noninvasive diagnostic strategy is promising, but should be further validated for different subtypes of breast cancers.
人们一直在探索用于乳腺癌检测的新型非侵入性诊断标志物。本研究的目的是利用一组亚洲华裔乳腺癌患者,识别循环 microRNA(miRNA)特征,并比较肿瘤和血清样本中的 miRNA 谱。
采用 microarray 或锁核酸实时 PCR 试剂盒,对 32 例患者的配对乳腺癌肿瘤、正常组织和血清样本中的 miRNA 进行全面分析。还将来自 22 例健康个体的血清样本作为正常对照。通过逻辑回归识别出有显著差异的血清 miRNA,并在来自患者(n=132)和健康对照者(n=101)的独立血清样本中进行验证。
在乳腺癌肿瘤中差异表达的 20 个最显著 miRNA 中,包括之前在乳腺癌中显示失调的 miRNA-21、miR-10b 和 miR-145。仅在肿瘤和血清中均过表达的 7 个 miRNA 提示 miRNA 可能是有选择地释放到血清中的。有趣的是,在血清样本中差异表达的 20 个最显著 miRNA 中有 16 个是新的。miR-1、miR-92a、miR-133a 和 miR-133b 被确定为最重要的诊断标志物,并成功得到验证;这些 miRNA 组合的受试者工作特征曲线的曲线下面积为 0.90 至 0.91。
miRNA 特征作为一种非侵入性诊断策略的临床应用具有广阔前景,但应针对不同类型的乳腺癌进一步验证。